- Q1 2024 Novartis AG Earnings Call TranscriptApr 23, 2024$97.28 (+2.27%)Earnings
- Novartis AG Annual Shareholders Meeting TranscriptMar 05, 2024
- MorphoSys AG to be Acquired by Novartis AG Call TranscriptFeb 06, 2024
- Q4 2023 Novartis AG Earnings Call TranscriptJan 31, 2024$103.47 (-3.97%)Earnings
- Novartis AG at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Novartis AG R&D Day TranscriptNov 28, 2023
- Novartis AG Impact & Sustainability Annual Event TranscriptNov 13, 2023
- Q3 2023 Novartis AG Earnings Call TranscriptOct 24, 2023$94.91 (+0.23%)Earnings
- Novartis AG PSMAfore Data at ESMO Presentation TranscriptOct 24, 2023
- Q2 2023 Novartis AG Earnings Call TranscriptJul 18, 2023$97.9 (+4.57%)Earnings
- Novartis AG - Sandoz Capital Markets Day (UK) TranscriptJun 12, 2023
- Novartis AG - Sandoz Capital Markets Day (USA) TranscriptJun 08, 2023
- Novartis AG at ASCO Investor Meeting (Virtual) TranscriptJun 05, 2023
- Q1 2023 Novartis AG Earnings Call TranscriptApr 25, 2023$98.45 (+3.43%)Earnings
- Novartis AG Annual Shareholders Meeting TranscriptMar 07, 2023
- Q4 2022 Novartis AG Earnings Call TranscriptFeb 01, 2023$83.49 (-2.64%)Earnings
- Novartis AG at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Novartis AG to Discuss Iptacopan ASH Update TranscriptDec 13, 2022
- Novartis AG Investor Update on Access & Sustainability TranscriptNov 30, 2022
- Q3 2022 Novartis AG Earnings Presentation TranscriptOct 25, 2022
- Meet Novartis AG Management Investor Event TranscriptSep 22, 2022
- Novartis AG Announces Intention to Separate Sandoz Business to Create a Standalone Company Call TranscriptAug 25, 2022
- Novartis AG Announces Intention to Separate Sandoz Business to Create a Standalone Company Call - Media TranscriptAug 25, 2022
- Q2 2022 Novartis AG Earnings Call TranscriptJul 19, 2022$81.38 (+3.99%)Earnings
- Q1 2022 Novartis AG Earnings Call TranscriptApr 26, 2022$84.18 (-1.64%)Earnings
- Novartis AG New Organizational Model Investor Call TranscriptApr 04, 2022
- Novartis AG Annual Shareholders Meeting TranscriptMar 04, 2022
- Q4 2021 Novartis AG Earnings Call TranscriptFeb 02, 2022$81.29 (-2.57%)Earnings
- Novartis AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Novartis AG Leqvio® FDA Approval Investor Call TranscriptDec 23, 2021
- Novartis AG R&D Day (Virtual) TranscriptDec 02, 2021
- Novartis AG at Novartis Co-Creating Impact Summit (Virtual) - Morning Session TranscriptDec 02, 2021
- Novartis AG Webinar: Integrating ESG Into Strategy TranscriptNov 12, 2021
- Q3 2021 Novartis AG Earnings Call TranscriptOct 26, 2021$80.28 (+1.78%)Earnings
- Novartis AG ESG Investor Day TranscriptSep 30, 2021
- Q2 2021 Novartis AG Earnings Call TranscriptJul 21, 2021$85.62 (+0.27%)Earnings
- Novartis AG Iptacopan (LNP023) Update Call TranscriptJun 22, 2021
- Novartis AG Oncology Update Call TranscriptJun 08, 2021
- Novartis AG Cardiovascular Update Call TranscriptMay 18, 2021
- Q1 2021 Novartis AG Earnings Call TranscriptApr 27, 2021$81.98 (-1.33%)Earnings
- Novartis AG Annual Shareholders Meeting TranscriptMar 02, 2021
- Novartis AG at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Novartis AG to Discuss Entresto® FDA Label Expansion Investor Q&A Call TranscriptFeb 17, 2021
- Novartis AG Materiality Assessment Webinar: Dialogue Matters TranscriptFeb 08, 2021
- Q4 2020 Novartis AG Earnings Call TranscriptJan 26, 2021$90.79 (-2.57%)Earnings
- Novartis AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Novartis AG, ABN Amro Bank NV & BlackRock Inc at Novartis Co-Creating Impact Summit (Virtual) - PM Session TranscriptDec 09, 2020
- Novartis AG at Novartis Co-Creating Impact Summit (Virtual) - AM Session TranscriptDec 09, 2020
- Virtual Meet Novartis AG Management Investor Event TranscriptNov 24, 2020
- Q3 2020 Novartis AG Earnings Call TranscriptOct 27, 2020$76.6 (-3.84%)Earnings
- Novartis AG ESG Investor Event TranscriptSep 01, 2020
- Novartis AG to Discuss Kesimpta® FDA Approval Investor Call TranscriptAug 21, 2020
- Q2 2020 Novartis AG Earnings Call TranscriptJul 21, 2020$81.4 (-2.26%)Earnings
- Novartis AG to Discuss the Oncology Pipeline Update Call TranscriptJun 15, 2020
- Novartis AG at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novartis AG Earnings Call TranscriptApr 28, 2020$83.31 (-1.73%)Earnings
- Novartis AG to Discuss Zolgensma® MDA Data Call TranscriptMar 30, 2020
- Novartis AG Annual Shareholders Meeting TranscriptFeb 28, 2020
- Q4 2019 Novartis AG Earnings Call TranscriptJan 29, 2020$90.6 (+0.21%)Earnings
- Salesforce.Com Inc, UnitedHealth Group Inc, Alphabet Inc, Color, and Novartis AG at JPMorgan Healthcare Conference Panel TranscriptJan 15, 2020
- Novartis AG at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Novartis AG R&D Day TranscriptDec 05, 2019
- Novartis AG to Acquire The Medicines Company for USD 9.7 Billion Call TranscriptNov 25, 2019
- Q3 2019 Novartis AG Earnings Call TranscriptOct 22, 2019$82.3 (+0.47%)Earnings
- Novartis AG to Discuss Beovu® FDA Approval Investor Call TranscriptOct 08, 2019
- Novartis AG to Discuss Kisqali® MONALEESA-3 ESMO Data Investor Call TranscriptOct 01, 2019
- Novartis AG to Discuss Ofatumumab (OMB157) ECTRIMS Data Investor Call TranscriptSep 16, 2019
- Novartis AG ESG Investor Event TranscriptSep 09, 2019
- Novartis AG to Discuss the Zolgensma® Update Call TranscriptAug 07, 2019
- Q2 2019 Novartis AG Earnings Call TranscriptJul 18, 2019$89.2 (+4.47%)Earnings
- Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call TranscriptMay 27, 2019
- Meet Novartis AG Management Investor Event - Breakout Sessions (Day 2) TranscriptMay 23, 2019
- Meet Novartis AG Management Investor Event - CEO Introduction (Day 2) TranscriptMay 23, 2019
- Novartis AG to Discuss Acquisition of Xiidra® from Takeda Pharmaceutical Co Ltd Call TranscriptMay 09, 2019
- Novartis AG to Discuss Zolgensma (AVXS-101) Clinical Data Call TranscriptMay 08, 2019
- Q1 2019 Novartis AG Earnings Call TranscriptApr 24, 2019$73.64 (+2.53%)Earnings
- Novartis AG at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean TranscriptApr 23, 2019
- Novartis AG Mayzent FDA Approval Investor Call TranscriptMar 27, 2019
- Novartis AG Annual Shareholders Meeting TranscriptFeb 28, 2019
Novartis AG to Discuss Ofatumumab (OMB157) ECTRIMS Data Investor Call Transcript
Good morning, and good afternoon, and welcome to the Novartis Investor Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) With that, I would like to hand over to Samir Shah, Global Head, Investor Relations. Please go ahead, sir.
Thank you very much, and good morning, and good afternoon, everybody. And thank you for taking the time to join us today as we go through the ECTRIMS data, which was presented last Friday. With myself in the room, we have Marie-France Tschudin. She is the -- as you know, she is the Head of Pharmaceuticals Division within Novartis. We also have Danny Bar-Zohar, who is the Global Development and Analytics Head; and Paul Spittle, who's the Global Commercial Head for Pharmaceuticals Division.
Before we actually start, just a couple of points to mention. The slides for this investor call are available on our website. And I'll also like to read you the safe harbor statement. The information presented today contains forward-looking statements that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)